ES2847025T3 - Productos génicos de expresión diferencial en tumores y su uso - Google Patents

Productos génicos de expresión diferencial en tumores y su uso Download PDF

Info

Publication number
ES2847025T3
ES2847025T3 ES18167570T ES18167570T ES2847025T3 ES 2847025 T3 ES2847025 T3 ES 2847025T3 ES 18167570 T ES18167570 T ES 18167570T ES 18167570 T ES18167570 T ES 18167570T ES 2847025 T3 ES2847025 T3 ES 2847025T3
Authority
ES
Spain
Prior art keywords
tumor
antibody
cells
associated antigen
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES18167570T
Other languages
English (en)
Spanish (es)
Inventor
Özlem Türeci
Ugur Sahin
Michael Koslowski
Stefan Fritz
Harald-Gerhard Geppert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ES2847025T3 publication Critical patent/ES2847025T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
ES18167570T 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso Expired - Lifetime ES2847025T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004024617A DE102004024617A1 (de) 2004-05-18 2004-05-18 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung

Publications (1)

Publication Number Publication Date
ES2847025T3 true ES2847025T3 (es) 2021-07-30

Family

ID=34968689

Family Applications (4)

Application Number Title Priority Date Filing Date
ES18167570T Expired - Lifetime ES2847025T3 (es) 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso
ES05745559.4T Expired - Lifetime ES2601149T3 (es) 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso
ES11002013.8T Expired - Lifetime ES2675558T3 (es) 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso
ES11002017.9T Expired - Lifetime ES2627962T3 (es) 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES05745559.4T Expired - Lifetime ES2601149T3 (es) 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso
ES11002013.8T Expired - Lifetime ES2675558T3 (es) 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso
ES11002017.9T Expired - Lifetime ES2627962T3 (es) 2004-05-18 2005-05-18 Productos génicos de expresión diferencial en tumores y su uso

Country Status (19)

Country Link
US (4) US9044382B2 (enExample)
EP (7) EP2380903B1 (enExample)
JP (5) JP5242160B2 (enExample)
AU (1) AU2005245593B2 (enExample)
CA (2) CA2563666C (enExample)
CY (4) CY1118271T1 (enExample)
DE (1) DE102004024617A1 (enExample)
DK (4) DK2371848T3 (enExample)
ES (4) ES2847025T3 (enExample)
HR (4) HRP20161449T1 (enExample)
HU (4) HUE040399T2 (enExample)
LT (4) LT1749027T (enExample)
ME (2) ME02889B (enExample)
PL (4) PL2380903T3 (enExample)
PT (4) PT3401327T (enExample)
RS (4) RS57437B1 (enExample)
SI (4) SI3401327T1 (enExample)
TR (1) TR201809165T4 (enExample)
WO (1) WO2005113587A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
AU2016202322B2 (en) * 2005-11-24 2018-03-08 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
JP2012518389A (ja) * 2009-02-25 2012-08-16 ダイアグノキュア インコーポレイテッド Ｇｉ癌の転移を検出するための方法
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN120518772A (zh) 2014-07-17 2025-08-22 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
US12186343B2 (en) 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
CA3122135A1 (en) * 2018-12-07 2020-06-11 Zlip Holding Limited Anti-claudin antibodies and uses thereof
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
WO2021111003A1 (en) 2019-12-06 2021-06-10 SOTIO a.s. Humanized cldn18.2 antibodies
PE20221830A1 (es) 2019-12-23 2022-11-29 Sotio Biotech A S Anticuerpos especificos contra la claudina 18.2 tumoral
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
PE20231561A1 (es) 2020-12-23 2023-10-03 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998A (en) 1841-03-12 Refrigerator
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
JPH05504476A (ja) 1989-12-27 1993-07-15 アメリカ合衆国 ヒト胃癌検出用診断プローブ
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5589579A (en) 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
WO2001016318A2 (en) * 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053757A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2000075316A1 (en) 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR19990077146A (ko) 1996-01-11 1999-10-25 길리스 스티브 유방암의 치료 및 진단용 조성물 및 방법
WO2000075327A1 (en) 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
WO2002016576A1 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. 11 human secreted proteins
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030022298A1 (en) 1997-09-15 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030073129A1 (en) 1998-09-01 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166104A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030008352A1 (en) 1997-09-18 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030170794A1 (en) 1997-09-18 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050196832A1 (en) 1997-09-18 2005-09-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030027272A1 (en) 1997-09-18 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7160985B2 (en) * 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030040471A1 (en) 1998-04-29 2003-02-27 Watson James D. Compositions isolated from skin cells and methods for their use
US20030022835A1 (en) 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
JP3428441B2 (ja) 1998-05-15 2003-07-22 エーザイ株式会社 タイトジャンクション構成膜蛋白質クローディンファミリー
US7351543B2 (en) 1998-06-02 2008-04-01 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US7319008B2 (en) 1998-06-02 2008-01-15 Genentech, Inc. Nucleic acid underexpressed in melanoma
EP1084142A4 (en) * 1998-06-11 2005-01-19 Smithkline Beecham Corp GPR35A RECEIVER
WO2000008206A1 (en) 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7026455B2 (en) 1998-09-01 2006-04-11 Genentech, Inc. Anti-pro 1343 antibodies
US20030082626A1 (en) 1998-09-01 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050181478A1 (en) 1998-09-01 2005-08-18 Baker Kevin P. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7041805B2 (en) 1998-09-01 2006-05-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2339043A1 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
EP1114152A2 (en) 1998-09-16 2001-07-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6143399A (en) * 1998-09-16 2000-04-03 Zymogenetics Inc. Stomach polypeptide zsig28
JP2004500011A (ja) 1998-10-06 2004-01-08 キュラゲン　コーポレイション 新規な分泌タンパク質、およびそれをコードするポリヌクレオチド
US7399834B2 (en) 1998-10-07 2008-07-15 Genentech, Inc. Anti-PRO1558 antibodies
US6235481B1 (en) * 1998-10-21 2001-05-22 Arch Development Corporation & Board Of Regents Polynucleotides encoding calpain 10
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7026449B2 (en) 1999-01-05 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2361840A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7507404B2 (en) 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4174183B2 (ja) 1999-03-23 2008-10-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
US20080286821A1 (en) 1999-05-14 2008-11-20 Eaton Dan L Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2287020T3 (es) 1999-06-02 2007-12-16 Genentech, Inc. Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE449109T1 (de) 1999-06-15 2009-12-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1205901A (en) 1999-10-14 2001-04-23 Board Of Trustees Of The University Of Arkansas, The Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof
JP2004522404A (ja) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
CA2390685C (en) 2000-01-06 2008-04-22 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
CA2394039A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030044890A1 (en) 2000-01-31 2003-03-06 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU2001237958A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. 22 human secreted proteins
AU2001247220A1 (en) 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001090357A1 (en) 2000-05-24 2001-11-29 Genesis Research & Development Corporation Limited Compositions isolated from skin cells and methods for their use
US6822082B2 (en) 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
CA2418725A1 (en) 2000-08-15 2002-02-21 Immunex Corporation Claudin polypeptides
AU2001285047A1 (en) 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20030017468A1 (en) 2000-08-28 2003-01-23 Sei-Yu Chen Compositions and methods relating to lung specific genes
WO2002020569A2 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
JP2004526411A (ja) 2000-09-18 2004-09-02 トマス・ジエフアーソン・ユニバーシテイ 胃および食道癌細胞を同定および標的とするための組成物および方法
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002066682A2 (en) 2001-01-29 2002-08-29 Phase-1 Molecular Toxicology, Inc. Rat toxicologically relevant genes and uses thereof
CA2439383A1 (en) * 2001-02-26 2002-09-06 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US20030152939A1 (en) 2001-04-09 2003-08-14 Glennda Smithson Novel secreted proteins and polynucleotides encoding them
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003000249A (ja) 2001-05-10 2003-01-07 Daiichi Fine Chemical Co Ltd クローディンによるＭＴ−ＭＭＰｓを介したｐｒｏＭＭＰ−２活性化
EP1446757A2 (en) * 2001-05-30 2004-08-18 Biomedical Center In silico screening for phenotype-associated expressed sequences
CA2450236A1 (en) 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
CA2457424A1 (en) 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030023042A1 (en) 2001-12-06 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003211398A1 (en) * 2002-02-28 2003-09-09 Sankyo Company, Limited Markers for predicting pathological conditions in haert failure and method of using the same
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
WO2003101283A2 (en) 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1578365A4 (en) 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1430902A1 (en) 2002-12-20 2004-06-23 Mondobiotech Laboratories Anstalt Pharmaceutical composition of interferon gamma with molecular diagnostics for the improved treatment of asthma bronchiale
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1677733A4 (en) 2003-10-03 2007-09-19 Bayer Pharmaceuticals Corp GENE EXPRESSION PROFILES AND METHOD OF USE
DE10354601B3 (de) 2003-11-21 2005-06-23 Chiropro Gmbh Gelenkprothese für Fingerglieder
WO2005052182A2 (en) 2003-11-26 2005-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method of analyzing plasma membrane protein content of cells
WO2005061548A1 (en) 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
WO2005076939A2 (en) 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease
CA2557181A1 (en) 2004-02-26 2005-09-09 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
US20050255041A1 (en) 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005114221A2 (en) 2004-05-21 2005-12-01 The Institute For Systems Biology Compositions and methods for quantification of serum glycoproteins
WO2006023121A1 (en) 2004-07-27 2006-03-02 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in white adipose tissue (13)
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
FR2876705B1 (fr) 2004-10-19 2008-12-12 Biomerieux Sa Procede pour le diagnostic d'une intolerance a l'aspirine
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
WO2007018843A2 (en) 2005-07-01 2007-02-15 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of influenza
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
WO2007027867A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP5405110B2 (ja) 2005-09-19 2014-02-05 ベリデックス・エルエルシー 原発不明がんの原発巣を同定するための方法および材料
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
MX2008012279A (es) 2006-03-29 2008-10-08 Genentech Inc Diagnostico y tratamientos para tumores.
US20100129929A1 (en) 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
WO2008082730A2 (en) 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008043561A2 (en) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
AU2007333106A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-20 regulated genes and pathways as targets for therapeutic intervention
BRPI0807227A2 (pt) 2007-02-01 2019-01-22 Veridex Llc métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JP2010529966A (ja) 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
JPWO2008152822A1 (ja) 2007-06-15 2010-08-26 株式会社メディネット 医薬
US20100292303A1 (en) 2007-07-20 2010-11-18 Birrer Michael J Gene expression profile for predicting ovarian cancer patient survival
WO2009035497A2 (en) 2007-08-08 2009-03-19 Savidge Tor C Disease related cysteine modifications and uses thereof
EP2036987A1 (en) 2007-09-17 2009-03-18 Siemens Healthcare Diagnostics GmbH Molecular markers for tumor cell content in tissue samples
US8653130B2 (en) 2007-09-19 2014-02-18 Suntory Holdings Limited Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s)
EP2944694B1 (en) 2007-10-12 2018-07-11 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Method for opening tight junctions
US8563515B2 (en) 2007-11-19 2013-10-22 The Regents Of The University Of Colorado, A Body Corporate Tight junction protein modulators and uses thereof
CA2726817A1 (en) 2008-06-02 2009-12-10 Nsabp Foundation, Inc. Identification and use of prognostic and predictive markers in cancer treatment
US20110190380A1 (en) 2008-10-23 2011-08-04 Elena Feinstein Methods for delivery of sirna to bone marrow cells and uses thereof
CN101381524A (zh) 2008-10-24 2009-03-11 南开大学 单层氧化石墨与水溶性高分子增强复合材料
GB0904957D0 (en) 2009-03-23 2009-05-06 Univ Erasmus Medical Ct Tumour gene profile
WO2010120526A2 (en) 2009-03-31 2010-10-21 Emory University Methods and systems for screening for and diagnosing dna methylation associated with autism spectrum disorders
CN101584860A (zh) 2009-04-27 2009-11-25 西安杰诺瓦生物科技有限公司 重组人Claudin18.2肿瘤疫苗及其制备方法
WO2010141093A2 (en) 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
AU2010302955A1 (en) 2009-10-01 2012-05-17 Chipdx Llc System and method for classification of patients
CA2782620A1 (en) 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
EP2366709A1 (en) 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
TR201809413T4 (tr) 2010-03-16 2018-07-23 Biontech Protein Therapeutics Gmbh Self-protein cldn18.2 ye karşı bir humoral immün yanıtı içeren tümor aşılama.
US8945847B2 (en) 2010-05-24 2015-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for ascertaining biosafety of an agent
MX2012013702A (es) * 2010-05-26 2013-03-21 Univ Minnesota Anticuerpos anti-cd133 de fragmento variable de cadena individual y usos de los mismos.
EP2576824A2 (en) 2010-06-07 2013-04-10 Roche Diagnostics GmbH Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US20130157891A1 (en) 2010-06-24 2013-06-20 Xiao-Jun Li Organ specific diagnostic panels and methods for identification of organ specific panel proteins
WO2012070014A2 (en) 2010-11-26 2012-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells
CN103119180A (zh) 2011-01-12 2013-05-22 森永乳业株式会社 产生具有免疫调节作用的乳的食物的筛选方法
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014025199A2 (ko) 2012-08-09 2014-02-13 주식회사 한독 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014025198A2 (ko) 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
EP2888391A4 (en) 2012-08-24 2016-09-14 Univ Utah Res Found COMPOSITIONS AND METHODS RELATING TO BLOOD-BASED BIOMARKERS FOR BREAST CANCER
US9856532B2 (en) 2012-09-07 2018-01-02 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (PTSD)
US20140073524A1 (en) 2012-09-07 2014-03-13 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (ptsd)
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer

Also Published As

Publication number Publication date
LT3401327T (lt) 2021-02-25
DK2380903T3 (en) 2017-07-17
US20080166350A1 (en) 2008-07-10
CY1119233T1 (el) 2018-02-14
JP5793133B2 (ja) 2015-10-14
US20170240646A1 (en) 2017-08-24
AU2005245593A1 (en) 2005-12-01
SI3401327T1 (sl) 2021-05-31
RS56140B1 (sr) 2017-10-31
PL1749027T3 (pl) 2017-01-31
ME02653B (me) 2017-06-20
US9775785B2 (en) 2017-10-03
ES2627962T3 (es) 2017-08-01
DK2371848T3 (en) 2018-07-23
WO2005113587A2 (de) 2005-12-01
HUE040399T2 (hu) 2019-03-28
EP3401327A1 (de) 2018-11-14
AU2005245593B2 (en) 2011-10-20
US20210145700A1 (en) 2021-05-20
HRP20161449T1 (hr) 2016-12-16
JP2013121346A (ja) 2013-06-20
PT3401327T (pt) 2021-02-11
SI1749027T1 (sl) 2017-01-31
HRP20170879T1 (hr) 2017-12-01
ME02889B (me) 2018-04-20
PL2380903T3 (pl) 2017-10-31
RS57437B1 (sr) 2018-09-28
EP2380903A1 (de) 2011-10-26
EP2383288A2 (de) 2011-11-02
EP2392593A3 (de) 2012-06-06
JP5242160B2 (ja) 2013-07-24
ES2675558T3 (es) 2018-07-11
JP6218881B2 (ja) 2017-10-25
EP1749027B1 (de) 2016-08-10
EP2392593A2 (de) 2011-12-07
US9044382B2 (en) 2015-06-02
TR201809165T4 (tr) 2018-07-23
SI2380903T1 (sl) 2017-08-31
RS61395B1 (sr) 2021-02-26
WO2005113587A3 (de) 2006-05-18
DE102004024617A1 (de) 2005-12-29
EP2371848A1 (de) 2011-10-05
LT2371848T (lt) 2018-07-25
CY1118271T1 (el) 2017-06-28
JP2016189775A (ja) 2016-11-10
SI2371848T1 (sl) 2018-10-30
EP2371848B8 (de) 2018-06-06
CY1123733T1 (el) 2022-05-27
EP2392593B1 (de) 2018-08-01
EP2383288A3 (de) 2012-02-15
CA2563666C (en) 2017-11-14
CA2984563A1 (en) 2005-12-01
PL2371848T3 (pl) 2018-12-31
PL3401327T3 (pl) 2021-05-04
JP2016185943A (ja) 2016-10-27
JP2015096504A (ja) 2015-05-21
CA2563666A1 (en) 2005-12-01
PT1749027T (pt) 2016-11-07
PT2371848T (pt) 2018-07-16
DK3401327T3 (da) 2021-04-06
PT2380903T (pt) 2017-07-12
LT2380903T (lt) 2017-07-10
CY1120789T1 (el) 2019-12-11
DK1749027T3 (en) 2016-12-05
EP3401327B1 (de) 2021-01-13
HRP20181013T1 (hr) 2018-08-24
JP6080831B2 (ja) 2017-02-15
EP2371848B1 (de) 2018-04-18
ES2601149T3 (es) 2017-02-14
JP2008508861A (ja) 2008-03-27
HUE030620T2 (en) 2017-06-28
JP6223488B2 (ja) 2017-11-01
HUE035289T2 (en) 2018-05-02
HRP20210494T1 (hr) 2021-05-14
EP2371849A1 (de) 2011-10-05
EP1749027A2 (de) 2007-02-07
EP2380903B1 (de) 2017-04-05
HUE056422T2 (hu) 2022-02-28
RS55357B1 (sr) 2017-03-31
LT1749027T (lt) 2016-11-10
US20150315287A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
ES2675785T3 (es) Productos génicos de expresión diferencial en tumores y su uso
ES2847025T3 (es) Productos génicos de expresión diferencial en tumores y su uso
ES2346067T3 (es) Identificacion de antigenos asociados a la superficie para el diagnostico y la terapia de tumores.
AU2015242979B2 (en) Genetic products differentially expressed in tumors and the use thereof
AU2012233044B2 (en) Genetic products differentially expressed in tumors and the use thereof
AU2011256897B2 (en) Genetic products differentially expressed in tumors and the use thereof